Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of moderate to severe active rheumatoid arthritis.
- Your doctor has already decided to start you on either upadacitinib (Rinvoq) or a TNF inhibitor (like adalimumab, etanercept, etc.) before you learn about this study.
- You have not taken upadacitinib before.
- If your doctor is prescribing a TNF inhibitor, you have not taken that specific TNF inhibitor before.
- You are not currently in another clinical trial with an investigational drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study compares two oral medications, tofacitinib and upadacitinib, when added to methotrexate for people with rheumatoid arthritis. The goal is to see which one works better and is safer for controlling symptoms.
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
Hear when a new Moderate to Severe Rheumatoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.